Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation

被引:53
作者
Candiloro, Ida L. M. [1 ,2 ]
Mikeska, Thomas [1 ,2 ]
Dobrovic, Alexander [1 ,2 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
关键词
MS-HRM; pyrosequencing; digital PCR; heterogeneous DNA methylation; DAPK1; chronic lymphocytic leukemia; MGMT PROMOTER METHYLATION; CPG ISLAND METHYLATION; PROTEIN-KINASE; GENE; HYPERMETHYLATION; EXPRESSION; PATTERNS; QUANTIFICATION; BLOOD;
D O I
10.4161/epi.6.4.14853
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heterogeneous DNA methylation leads to difficulties in accurate detection and quantification of methylation. Methylation-sensitive high resolution melting (MS-HRM) is unique among regularly used methods for DNA methylation analysis in that heterogeneous methylation can be readily identified, although not quantified, by inspection of the melting curves. Bisulfite pyrosequencing has been used to estimate the level of heterogeneous methylation by quantifying methylation levels present at individual CpG dinucleotides. Sequentially combining the two methodologies using MS-HRM to screen the amplification products prior to bisulfite pyrosequencing would be advantageous. This would not only replace the quality control step using agarose gel analysis prior to the pyrosequencing step but would also provide important qualitative information in its own right. We chose to analyze DAPK1 as it is an important tumor suppressor gene frequently heterogeneously methylated in a number of malignancies, including chronic lymphocytic leukemia (CLL). A region of the DAPK1 promoter was analyzed in 10 CLL samples by MS-HRM. By using a biotinylated primer, bisulfite pyrosequencing could be used to directly analyze the samples. MS-HRM revealed the presence of various extents of heterogeneous DAPK1 methylation in all CLL samples. Further analysis of the biotinylated MS-HRM products by bisulfite pyrosequencing provided quantitative information for each CpG dinucleotide analyzed, and confirmed the presence of heterogeneous DNA methylation. Whereas each method could be used individually, MS-HRM and bisulfite pyrosequencing provided complementary information for the assessment of heterogeneous methylation.
引用
收藏
页码:501 / 508
页数:8
相关论文
共 36 条
[1]   DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? [J].
Aggerholm, A ;
Hokland, P ;
Guldberg, P .
BLOOD, 2000, 95 (09) :2997-2998
[2]   BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing [J].
Bock, C ;
Reither, S ;
Mikeska, T ;
Paulsen, M ;
Walter, J ;
Lengauer, T .
BIOINFORMATICS, 2005, 21 (21) :4067-4068
[3]   Quantitative high-resolution CpG island mapping with Pyrosequencing™ reveals disease-specific methylation patterns of the CDKN2B gene in Myelodysplastic syndrome and myeloid leukemia [J].
Brakensiek, Kai ;
Wingen, Luzie U. ;
Langer, Florian ;
Kreipe, Hans ;
Lehmann, Ulrich .
CLINICAL CHEMISTRY, 2007, 53 (01) :17-23
[4]   Detection of MGMT Promoter Methylation in Normal Individuals Is Strongly Associated with the T Allele of the rs16906252 MGMT Promoter Single Nucleotide Polymorphism [J].
Candiloro, Ida L. M. ;
Dobrovic, Alexander .
CANCER PREVENTION RESEARCH, 2009, 2 (10) :862-867
[5]   Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene [J].
Candiloro, Ida L. M. ;
Mikeska, Thomas ;
Hokland, Peter ;
Dobrovic, Alexander .
EPIGENETICS & CHROMATIN, 2008, 1 (1)
[6]   Sensitive and quantitative universal Pyrosequencing™ methylation analysis of CpG sites [J].
Colella, S ;
Shen, L ;
Baggerly, KA ;
Issa, JPJ ;
Krahe, R .
BIOTECHNIQUES, 2003, 35 (01) :146-+
[7]  
COSTELLO JF, 1994, J BIOL CHEM, V269, P17228
[8]  
Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO
[9]  
2-R
[10]   Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy [J].
Dunn, J. ;
Baborie, A. ;
Alam, F. ;
Joyce, K. ;
Moxham, M. ;
Sibson, R. ;
Crooks, D. ;
Husband, D. ;
Shenoy, A. ;
Brodbelt, A. ;
Wong, H. ;
Liloglou, T. ;
Haylock, B. ;
Walker, C. .
BRITISH JOURNAL OF CANCER, 2009, 101 (01) :124-131